Erythropoietin and Neonatal Neuroprotection

Sandra E Juul; Gillian C Pet

doi:10.1016/j.clp.2015.04.004

Erythropoietin and Neonatal Neuroprotection

Clin Perinatol. 2015 Sep;42(3):469-81. doi: 10.1016/j.clp.2015.04.004. Epub 2015 May 14.

Authors

Sandra E Juul¹, Gillian C Pet²

Affiliations

¹ Division of Neonatology, Department of Pediatrics, University of Washington, 1959 Northeast Pacific Street, Box 356320, Seattle, WA 98195-6320, USA. Electronic address: sjuul@uw.edu.
² Division of Neonatology, Department of Pediatrics, University of Washington, 1959 Northeast Pacific Street, Box 356320, Seattle, WA 98195-6320, USA.

Abstract

Certain groups of neonates are at high risk of developing long-term neurodevelopmental impairment and might be considered candidates for neuroprotective interventions. This article explores some of these high-risk groups, relevant mechanisms of brain injury, and specific mechanisms of cellular injury and death. The potential of erythropoietin (Epo) to act as a neuroprotective agent for neonatal brain injury is discussed. Clinical trials of Epo neuroprotection in preterm and term infants are updated.

Keywords: Apoptosis; Autophagy; Brain injury; Erythropoietin; Extreme prematurity; Hypoxic ischemic encephalopathy; Necrosis.

Publication types

Review

MeSH terms

Erythropoietin / therapeutic use*
Humans
Hypoxia-Ischemia, Brain / prevention & control*
Infant, Newborn
Neuroprotection*

Substances

Erythropoietin

Abstract

Publication types

MeSH terms

Substances

Grants and funding